BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 19, 2025
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Other news to note for Dec. 22, 2021

Dec. 22, 2021
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Affiris, Biondvax, Claritas, Cocrystal, Arcus, Cytonus, Durect, Dyadic, Frontier, Gilead, Innocoll, RDIF, Replicel, Salzman Scandinavian, Shiseido, Titan, Vaxalta, Viewpoint.
Read More

In the clinic for Dec. 22, 2021

Dec. 22, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aldeyra, Allakos, Alnylam, Clearside, Eiger, Eli Lilly, Medigene, Novaliq, Novaremed, Novavax, Pfizer, Phasebio, Repare, /Rigel, Statera, Telix, TFF, Urogen, Urovant, Valneva, Vifor.
Read More
Man uses smartphone to take picture of BD Veritor At-Home COVID-19 test

BD closes acquisition of Scanwell as demand for Veritor at-home test surges

Dec. 21, 2021
By Annette Boyle
Becton, Dickinson and Co. (BD) completed its acquisition of Scanwell Health Inc., its partner in development of the smartphone-enabled BD Veritor At-Home COVID-19 Test, just in time for increased demand driven by the Omicron surge in the U.S. and plans to make the tests available for free by the federal government as well as several states and large municipalities. Currently, most of the tests distributed by governments are made by Abbott Laboratories, which received emergency use authorization (EUA) for its at-home test in March 2021.
Read More
Digital illustration of U.S., coronavirus

US promises surge in at-home COVID-19 tests, but can companies deliver?

Dec. 21, 2021
By Mark McCarty
As the Omicron variant of COVID-19 sweeps across the globe, the Biden administration has announced a program to purchase 500 million rapid antigen tests to help slow the pandemic. The news comes at an especially critical time, given the increased transmissibility of the Omicron variant, but the promised volume is unlikely to be achieved by the first day of January 2022.
Read More
British pound symbol

Bond Digital Health to expand digital lateral flow tool beyond COVID-19

Dec. 21, 2021
By Catherine Longworth
Bond Digital Health Ltd. landed £1 million (US$1.3 million) from investors to expand development of its Transform data management system for lateral flow diagnostic tests. The technology connects to an app that captures data from lateral flow assays in self-testing settings. The results are then shared to a dashboard that can be monitored by the platform admin. The new investment included equity funding from the Development Bank of Wales and high-net-worth investment service Wealth Club. In addition to the current round, Bond is aiming to raise a further £500,000 by January.
Read More

Other news to note for Dec. 21, 2021

Dec. 21, 2021
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Access Strategy Partners, Aurora Spine, Avero Diagnostics, Biosig Technologies, Emulate, Heraeus Holding, Jolly Good, Medina Healthcare, Nanovibronix, Norwood Medical, Precision Manufacturing, Progenity, Steribite, Thermo Fisher Scientific.
Read More

In the clinic for Dec. 21, 2021

Dec. 21, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Fast Biomedical, Ondine.
Read More

COVID-19 holiday wrapping: Data from Aridis and Moderna show strength against Omicron

Dec. 21, 2021
By Lee Landenberger
Aridis Pharmaceuticals Inc. is one of two companies posting COVID-19 data just days before Christmas. Its fully human monoclonal antibody cocktail, AR-701, was shown to be broadly reactive against COVID-19 variants, including Omicron, in preclinical research. Moderna Inc. also posted new data that showed preliminary neutralizing data against Omicron following 50-mg doses of its vaccine, which is currently authorized, and 100-mg dose boosters, which increased neutralizing antibody levels 83-fold from the pre-boost levels.
Read More

Providence and Everest’s vaccine is first mRNA in WHO’s Solidarity Trial Vaccines study

Dec. 21, 2021
By David Ho
Everest Medicines Ltd. and Providence Therapeutics Holdings Inc.’s COVID-19 vaccine was cleared for inclusion in the World Health Organization’s (WHO) Solidarity Trial Vaccines clinical trial.
Read More

Regulatory actions for Dec. 21, 2021

Dec. 21, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Advicenne, Alnylam, Argenx, Astrazeneca, Bluebird, Cara, Coherus, Edenbridge, Editas, Everest, GBT, Intra-Cellular, Lannett, Lysogene, Moderna, Novavax, Polarityte, Poseida, Providence, Sorrento, Takeda, Telix, Zogenix.
Read More
Previous 1 2 … 149 150 151 152 153 154 155 156 157 … 551 552 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Rare disease illustration

    Rare earth: Biomarin to use global reach post-$4.8B Amicus buy

    BioWorld
    Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing